8-K: Eli Lilly Completes Acquisition of Centessa Pharmaceuticals

Centessa Pharmaceuticals has been acquired by Eli Lilly and Company in a transaction valued at $38.00 per share plus contingent value rights.

Summary

• Eli Lilly and Company has completed the acquisition of Centessa Pharmaceuticals via a court-sanctioned scheme of arrangement.
• Shareholders are entitled to $38.00 in cash per share.
• Shareholders also receive one non-transferable contingent value right (CVR) per share, potentially worth up to an additional $9.00 based on future milestones.
• Centessa has become a wholly owned subsidiary of Eli Lilly.
• All outstanding indebtedness under the December 2024 Loan and Security Agreement has been repaid in full and the agreement terminated.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive outcome for shareholders, as the acquisition provides a significant cash exit and potential upside through CVRs.

Positives

• Shareholders receive a definitive cash consideration of $38.00 per share.
• Potential for additional upside through CVRs valued at up to $9.00 per share.
• Full repayment of corporate debt obligations upon closing.

Negatives

• The company will no longer trade as an independent public entity.
• All existing equity incentive plans and outstanding options/RSUs have been settled or cancelled, ending public shareholder participation in future growth.

Risks

• The $9.00 per share CVR value is contingent upon specific, undisclosed milestones, meaning there is no guarantee of receiving the full amount.
• The CVRs are non-transferable, limiting liquidity for former shareholders.

Future Outlook

As a wholly owned subsidiary of Eli Lilly, Centessa will no longer provide independent public financial guidance or reporting.

Management Comments

• The company has transitioned to new leadership under appointees Christopher Stokes and Kristina Mignon Wright.

Industry Context

StockSavvy.ai notes that this acquisition follows a broader trend of large-cap pharmaceutical companies like Eli Lilly aggressively acquiring specialized biotech firms to bolster their R&D pipelines and secure proprietary drug candidates.

Comparison to Industry Standards

• The acquisition structure, utilizing a mix of upfront cash and CVRs, is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The $38.00 cash premium is consistent with recent mid-cap biotech acquisition multiples observed in the sector.

Management Changes

Corporate Governance

Legal Proceedings

• The acquisition was subject to a court-sanctioned scheme of arrangement under the UK Companies Act 2006.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders receive cash and CVRs.
• Employees and management face significant leadership and organizational changes.
• Creditors have been satisfied through the full repayment of existing debt.

Next Steps

• Deregistration of American Depositary Shares with the SEC.
• Suspension of reporting obligations under the Exchange Act.
• Integration of Centessa operations into Eli Lilly.

Key Dates

Keywords

Acquisition, Eli Lilly, Centessa Pharmaceuticals, Merger, Biotech, CVR, Delisting